Potential roles for pharmacists in pharmacogenetics

Journal of the American Pharmacists Association

Volumn 48, Issue 2, 2008, Pages

  El Ibiary, Shareen Y ^a   Cheng, Christine ^a   Alldredge, Brian ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pharmacists; Pharmacogenetics; Research

Indexed keywords

EDUCATION; HUMAN; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACOGENETICS; PROFESSIONAL STANDARD; REVIEW;

BIOMEDICAL RESEARCH; EDUCATION, PHARMACY, CONTINUING; HUMANS; PHARMACISTS; PHARMACOGENETICS; PROFESSIONAL ROLE; RESEARCH DESIGN;

EID: 42149168055     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2008.07050     Document Type: Article

References (52)

1. Ito RK, Demers LM. Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in the clinical diagnostic laboratory. Clin Chem. 2004;50:1526-7.
2. Brock TP, Valgus JM, Smith SR, Summers KM. Pharmacogenomics: implications and considerations for pharmacists. Pharmacogenomics. 2003;4:321-30.
3. Johnson JA, Bootman JL, Evans WE, et al. Pharmacogenomics: a scientific revolution in pharmaceutical sciences and pharmacy practice: report of the 2001-2002 Academic Affairs Committee. Accessed at www.ajpe.org/legacy/pdfs/ aj6604S03.pdf, January 3, 2007.
4. Clemerson JP, Payne K, Bissell P, Anderson C. Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci. 2006;28:126-30.
5. Carrico JM. Human Genome Project and pharmacogenomics: implications for pharmacy. J Am Pharm Assoc. 2000;40:115-6.
6. How genetics could change pharmacy. The Pharmaceutical Journal. 2003;270:508-9.
7. Zagaria M. The promise of pharmacogenomics: optimizing drug therapy while limiting toxicity. Accessed at www.uspharmacist. com/index.asp?show= article&page=8-1190.htm, January 14, 2008.
8. Vizirianakis IS. Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur J Pharm Sci. 2002;15:243-50.
9. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics. 2004;5:571-9.
10. Lunshof J. Teaching and practicing pharmacogenomics: a complex matter. Pharmacogenomics. 2006;7:243-6.
11. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 2005;5:221-5.
12. Gibbs N. The secret of life. TIME Magazine. 2003;161(7):42-5.
13. Freimer N, Sabatti C. The human phenome project. Nat Genet. 2003;34:15-21.
14. Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med. 2002;347:1512-20.
15. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet. 2005;37:671-81.
16. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov. 2004;3:763-9.
17. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641-7.
18. Donovan JL, Drake JA, Whittaker P, Tran MT. Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis. 2006;22:23-30.
19. Tschol N, Lai DK, Tilley JA, et al. Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients. Can J Cardiol. 2003;19:1413-7.
20. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist- managed antiepileptic drug therapy. Pharmacotherapy. 2006;26:1369-78.
21. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9:269-73.
22. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1508-16.
23. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-71.
24. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995;108(4 suppl):276S-290S.
25. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-28.
26. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 2003;3:202-14.
27. Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002;194:267-73.
28. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 1995;5:389-92.
29. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-8.
30. FDA approves updated warfarin (Coumadin) prescribing information. Accessed at www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html, January 14, 2008.
31. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645-9.
32. Oren E, McCart G, Phillips KA. Evaluating the potential impact of pharmacogenomics on ADRs. J Manag Care Pharm. 2002;8:285-90.
33. Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985;42:304-8.
34. Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist- managed anticoagulation service. Ann Pharmacother. 2000;3:567-72.
35. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-33.
36. Phillips KA, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev. 2006;63:301-26.
37. Ezzeldin HH, Diasio RB. Genetic testing in cancer therapeutics. Clin Cancer Res. 2006;12:4137-41.
38. Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005;10:104-11.
39. Camptosar [package insert]. New York: Pfizer; 2006.
40. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006;106:1007-16.
41. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-8.
42. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-7.
43. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985-9.
44. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293-301.
45. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-9.
46. Purinethol [package insert]. Greenville, N.C.: DSM Pharmaceuticals: 2003.
47. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics. 2005;15:365-9.
48. Van Bebber SL, Keegan HL, Phillips KA, Issa AM. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Future Medicine. 2006;3:415-9.
49. Toxicity/benefit ratio optimization of chemotherapy in colorectal cancer (CRC) patients by determination of individual genotype determinants. Accessed at www.clinicaltrials.gov/ct/ show/NCT00138060?order=1, December 7, 2006.
50. DHPLC determination of TPMT polymorphisms. Accessed at www.clinicaltrials.gov/ct/show/NCT00402090?order=1, December 7, 2006.
51. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7:783-92.
52. Hampton T. Researchers draft guidelines for clinical use of pharmacogenomics. JAMA. 2006;296:1453-4.